Innoviva, Inc. INVA Durlobactam — Royalty Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Innoviva, Inc.'s durlobactam — royalty expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Innoviva, Inc.'s durlobactam — royalty expense?
- Innoviva, Inc. (INVA) reported durlobactam — royalty expense of $0 in Q1 2026.
- What does durlobactam — royalty expense mean?
- This metric captures the costs incurred for the right to use intellectual property or licensed technology associated with the production or sale of a specific product segment. It represents the ongoing financial obligation paid to third-party licensors based on the commercial performance of the underlying asset. Monitoring this expense is essential for evaluating the net profitability and margin structure of the segment.